VTRO (Vitro Biopharma) Net Margin %: -208.32% (As of Oct. 2022)

What is Vitro Biopharma Net Margin %?

Vitro Biopharma VTRO Net Margin % is -208.32% as of Oct. 2022. The stock has 6 warning signs investors should review.

Net margin is calculated as Net Income divided by its Revenue. Vitro Biopharma's Net Income for the three months ended in Oct. 2022 was $-6.86 Mil. Vitro Biopharma's Revenue for the three months ended in Oct. 2022 was $3.29 Mil. Therefore, Vitro Biopharma's net margin for the quarter that ended in Oct. 2022 was -208.32%.

The historical rank and industry rank for Vitro Biopharma's Net Margin % or its related term are showing as below:

VTRO' s Net Margin % Range Over the Past 10 Years
Min: -4516.67 Med: -296.71 Max: -60.87
Current: -208.32

VTRO's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -88.815 vs VTRO: -208.32

Vitro Biopharma (AMEX:VTRO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Vitro Biopharma Net Margin % Related Terms

Vitro Biopharma Net Margin % Historical Data

* Premium members only.

The historical data trend for Vitro Biopharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma Net Margin % Chart

Vitro Biopharma Annual Data

Trend

Oct09

Oct10

Oct11

Oct12

Oct13

Oct14

Oct15

Oct17

Oct21

Oct22

Net Margin %

Get a 7-Day Free Trial

-172.73

-248.48

-171.76

-344.93

-208.32

Vitro Biopharma Quarterly Data
	Oct00	Oct01	Oct02	Oct03	Oct04	Oct05	Oct06	Oct07	Oct08	Oct09	Oct10	Oct11	Oct12	Oct13	Oct14	Oct15	Oct17	Oct21	Oct22
Net Margin %	Get a 7-Day Free Trial														-172.73	-248.48	-171.76	-344.93	-208.32

VTRO vs : Net Margin % Comparison

For the Biotechnology subindustry, Vitro Biopharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vitro Biopharma Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vitro Biopharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Vitro Biopharma's Net Margin % falls into.

Save Embed

Vitro Biopharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Vitro Biopharma's Net Margin for the fiscal year that ended in Oct. 2022 is calculated as

Net Margin	=	Net Income (A: Oct. 2022 )	/	Revenue (A: Oct. 2022 )
	=	-6.86	/	3.293
	=	-208.32 %

Vitro Biopharma's Net Margin for the quarter that ended in Oct. 2022 is calculated as

Net Margin	=	Net Income (Q: Oct. 2022 )	/	Revenue (Q: Oct. 2022 )
	=	-6.86	/	3.293
	=	-208.32 %

Frequently Asked Questions Learn more about Net Margin % →

What does a Net Margin % of -208.32% mean?

Vitro Biopharma (VTRO) has a Net Margin % of -208.32% as of Oct. 2022. Net margin is the ratio of total net income to net sales. View historical data on Vitro Biopharma and its competitors.

Is Vitro Biopharma's Net Margin % too high?

Vitro Biopharma's current Net Margin % is -208.32%.

How does Vitro Biopharma's Net Margin % compare to ?

Vitro Biopharma's Net Margin % of -208.32% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Net Margin % for a Biotechnology company?

A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Net Margin % mean?

A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vitro Biopharma and its competitors. Vitro Biopharma's current Net Margin % is -208.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vitro Biopharma stock overvalued right now?

Vitro Biopharma (VTRO) has a current Net Margin % of -208.32%. The current Net Margin % is -208.32%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Net Margin % calculated?

Net Margin % is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current Net Margin % is -208.32% as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitro Biopharma Business Description

Industry Healthcare Biotechnology

Comparable Companies

Address 4621 Technology Drive, Golden, CO, USA, 80403

Website http://www.vitrobiopharma.com

Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.